Training programme on understanding and biomarking the genetic and immunological determinants of melanoma survival.
Human R&D, Training
H2020-MSCA-ITN-2014 – Grant Agreement ID 641458
1 June 2015 to 31 December 2019
In order to improve the survival of melanoma patients with advanced disease, improved and personalized therapy selection is warranted. A key MELGEN project aim is to identify patient characteristics and his/her individual cancer characteristics that allow for drug response prediction. This is often called personalized medicine, and tests which allow medical teams to advise the patient about what treatment is likely to be best for them are called predictive biomarkers. The MELGEN project was designed as an environment for long-term, collaborative, cancer genetics research with the central aim of improving precision (personalized) medicine. Within the consortium, GenomeScan hosted an early stage researcher (ESR), several secondments, coordinated the “Introduction to Genomics” course, and led the work package utilizing the new genomic technologies.
Genome-wide characterization of 5-hydoxymethylcytosine in melanoma reveals major differences with nevus. Salgado C, et al. Genes Chromosomes Cancer. 2020 Feb 3. doi: 10.1002/gcc.22837
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 641458.